This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hodgkin lymphoma호지킨림프종

Classification codes C81 (KCD-8 / ICD-10)
Special Copayment Reduction V193 · 5 years from the cancer patient registration date · 5% copayment
Synonyms Hodgkin's disease, classical Hodgkin lymphoma (cHL), nodular sclerosis, mixed cellularity, lymphocyte depletion, lymphocyte-rich, nodular lymphocyte predominant (NLPHL)
Adult onset Not low — bimodal distribution: first peak at ages 15-35, second peak after age 50

Contents

A.Classification codesB.Synonyms
1.History2.Causes
3.Genetics4.General epidemiology
5.Pathophysiology6.Symptoms
7.Signs8.Screening
9.Diagnosis10.Treatment
11.Prognosis12.Prevention
13.References

A. Classification codes

CodeName
C81Hodgkin lymphoma
C81.0Lymphocyte predominant Hodgkin lymphoma
C81.1Nodular sclerosis Hodgkin lymphoma
C81.2Mixed cellularity Hodgkin lymphoma
C81.3Lymphocyte depleted Hodgkin lymphoma
C81.4Lymphocyte-rich classical Hodgkin lymphoma
C81.7Other classical Hodgkin lymphoma
C81.9Hodgkin lymphoma, unspecified

B. Synonyms

Hodgkin's disease, classical Hodgkin lymphoma (cHL), nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), Reed-Sternberg cell lymphoma. In Korea, the older Korean terms "Hodgkin-ssi-byeong" and "Hodgkin-byeong" (Hodgkin's disease) are also used, and the current standard name is "Hodgkin lymphoma." In the WHO 2022 classification, NLPHL was renamed "nodular lymphocyte predominant B-cell lymphoma (NLPBL)."


1. History

In 1832, the British pathologist Thomas Hodgkin at Guy's Hospital in London presented "On Some Morbid Appearances of the Absorbent Glands and Spleen," describing distinctive lesions involving the neck, mediastinum, and spleen. Some of the 7 cases he described are recognized as the first records of what is now Hodgkin lymphoma. The disease was named Hodgkin's disease after him.

In 1898 the Austrian pathologist Carl Sternberg, and in 1902 the American pathologist Dorothy Reed, independently described the pathological hallmark cell of Hodgkin's disease—a giant cell with two nuclei and prominent nucleoli. This cell was named the Reed-Sternberg cell (RS cell) after the two and became the diagnostic marker of Hodgkin lymphoma.

In the early to mid-20th century, radiation therapy was the main treatment. In the 1930s–50s, Henry Kaplan and Saul Rosenberg systematized extended field radiation, showing that cure was possible in early-stage patients. In 1964, Vincent DeVita et al. developed the MOPP regimen (nitrogen mustard + vincristine + procarbazine + prednisone), achieving a cure rate of 54% in advanced Hodgkin lymphoma. This was one of the first cases of curing a solid malignancy with multiagent chemotherapy. In the 1970s–80s, the ABVD regimen (doxorubicin + bleomycin + vinblastine + dacarbazine) was developed with efficacy similar to MOPP and reduced toxicity (reduced gonadal toxicity and risk of secondary leukemia), and it remains the basis of standard treatment to this day.

Since the 2000s, the introduction of PET-CT has revolutionized treatment response assessment. PET-adapted therapy—reducing treatment intensity when interim PET is negative and intensifying when PET is positive—became the standard. In 2011, brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate (ADC), was approved for treatment of relapsed/refractory Hodgkin lymphoma, and the ECHELON-1 study demonstrated (2018) that BV-AVD showed superior progression-free survival compared with ABVD in first-line treatment of advanced Hodgkin lymphoma. In 2024, the SWOG S1826 study showed that NIVO-AVD (nivolumab + AVD) had significantly superior progression-free survival and better tolerability compared with BV-AVD in first-line treatment of advanced-stage disease, emerging as the new standard treatment for advanced Hodgkin lymphoma.

2. Causes

Epstein-Barr virus (EBV): EBV is involved in about 30-40% of classical Hodgkin lymphoma (cHL). The EBV-related proportion is particularly high in the mixed cellularity subtype, HIV-associated Hodgkin lymphoma, and pediatric and elderly patients. After infecting B cells, EBV expresses LMP1 and LMP2A, activating NF-κB signaling and inhibiting apoptosis, thereby promoting tumorigenesis. In young adults with a history of infectious mononucleosis, the risk of developing Hodgkin lymphoma increases 3-4-fold.

HIV infection: The risk of Hodgkin lymphoma increases 5-15-fold in HIV-positive patients. HIV-associated Hodgkin lymphoma is often of the mixed cellularity type, has a high EBV-related proportion, and often presents at an advanced stage. Despite the widespread use of antiretroviral therapy (ART), HIV-associated Hodgkin lymphoma remains a clinical problem.

Immunodeficiency: The risk of Hodgkin lymphoma increases with immunosuppression after organ transplantation and with congenital immunodeficiency (common variable immunodeficiency, CVID). The risk is also slightly increased in autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis).

Genetic predisposition: The risk of disease is increased in identical twins of patients with Hodgkin lymphoma, and the risk among siblings is also higher than in the general population. Specific HLA types (HLA-A1, HLA-B5, HLA-B8, HLA-B18) are associated with susceptibility.

Socioeconomic factors: A "delayed infection hypothesis" has been proposed: in developing countries, EBV exposure occurs early in childhood and the immune response differs, whereas in developed countries EBV infection is concentrated in adolescence, raising the risk of infectious mononucleosis and Hodgkin lymphoma.

3. Genetics

The Reed-Sternberg (RS) cell, the tumor cell of Hodgkin lymphoma, derives from germinal center B cells but shows a distinctive immunophenotype, expressing almost none of the B-cell lineage markers (CD20, CD79a).

Aberrant activation of the NF-κB pathway: This is the key survival signal of RS cells. REL/NF-κB gene amplification, IκB (NF-κB inhibitor) mutation/loss, and NF-κB activation by LMP1 (EBV) or CD30 signaling induce apoptosis resistance in RS cells. REL amplification is frequent in nodular sclerosis.

JAK-STAT pathway abnormalities: JAK2 amplification (9p24.1 amplification) and STAT6 mutations are major molecular changes in Hodgkin lymphoma. 9p24.1 amplification, together with JAK2 amplification, induces PD-L1 (CD274) overexpression, a key mechanism of immune evasion. PD-L1/PD-L2 overexpression protects RS cells from T-cell immune attack.

PD-L1 overexpression and immune checkpoint inhibitor targeting: PD-L1 overexpression due to 9p24.1 amplification is the molecular basis explaining the excellent treatment response to anti-PD-1 immune checkpoint inhibitors such as nivolumab and pembrolizumab. The overall response rate of anti-PD-1 therapy in Hodgkin lymphoma reaching about 70-90% in relapsed/refractory patients is attributable to this distinctive molecular feature.

CD30 expression: A universal surface antigen of RS cells and the target of brentuximab vedotin (BV, an anti-CD30 ADC). CD30 expression is confirmed by immunohistochemistry and is an essential prerequisite for BV treatment.

Other molecular changes: TNFAIP3 (A20) mutations (loss of a negative regulator of NF-κB), NFKBIA mutations, SOCS1 mutations (loss of a negative regulator of JAK-STAT), and numerical chromosomal abnormalities (hyperploidy, aneuploidy) are observed in RS cells. Nodular lymphocyte predominant type (NLPHL) includes BCL6, PRMD1, and SGK1 mutations and has a molecular profile similar to GCB-type DLBCL.

4. General epidemiology

Hodgkin lymphoma accounts for about 10-15% of all lymphomas, with about 83,000 new diagnoses worldwide each year. In Western countries it accounts for 0.5-1% of all malignancies.

Age distribution: In Western countries, a bimodal age distribution is characteristic, with a first peak at ages 15-35 and a second peak after age 50. In Korea, the CISL (Consortium for Improving Survival of Lymphoma) study reported a distribution close to unimodal, with the first peak at ages 16-30. This is a pattern commonly observed in Asia and developing countries, reflecting differences in socioeconomic factors and patterns of EBV infection.

Epidemiology in Korea: According to national cancer registry statistics, about 1,000-1,200 new cases of Hodgkin lymphoma are diagnosed each year, accounting for about 8-10% of all lymphomas. Compared with Western countries, the incidence is lower, the proportion of mixed cellularity is relatively higher, and the EBV-associated proportion is high. Childhood and adolescent Hodgkin lymphoma is being systematically analyzed in multicenter studies of the KPHOG (Korean Pediatric Hematology Oncology Group).

Distribution of histologic subtypes: Nodular sclerosis (NS) is the most common, accounting for about 60-70%, followed by mixed cellularity (MC) about 15-25%, lymphocyte-rich (LR) about 5%, lymphocyte depletion (LD) less than 1%, and nodular lymphocyte predominant (NLPHL) about 5%. In Korea, the proportion of mixed cellularity is relatively higher than in Western countries.

5. Pathophysiology

Origin of the Reed-Sternberg cell: Molecular biological studies have shown that RS cells derive from germinal center B cells. RS cells originate from a single clone that has already undergone B-cell receptor (BCR) rearrangement and bear traces of somatic hypermutation of the immunoglobulin heavy and light chains. Paradoxically, however, RS cells have lost BCR expression and are cells that would normally be eliminated by apoptosis (BCR-negative B cell apoptosis). Constitutive activation of NF-κB prevents apoptosis of these cells unfit for survival.

Tumor microenvironment (TME): A distinctive feature of Hodgkin lymphoma is that the tumor cells (RS cells) make up less than 1% of the entire tumor tissue, and the remaining 99% or more consists of reactive non-neoplastic cells—T lymphocytes, B lymphocytes, eosinophils, plasma cells, histiocytes, and fibroblasts. Cytokines secreted by RS cells (IL-5, IL-13, TARC/CCL17, MDC/CCL22, Galectin-1, etc.) attract these reactive cells and create an immunosuppressive environment.

PD-L1 overexpression and immune evasion: Simultaneous overexpression of JAK2 and PD-L1/PD-L2 due to chromosome 9p24.1 amplification is characteristic. PD-L1 binds to PD-1 on T cells and blocks the antitumor immune response. This mechanism explains the high sensitivity of Hodgkin lymphoma to anti-PD-1 therapy. In addition, TARC/CCL17 attracts Th2 T cells and regulatory T cells (Treg), reinforcing the immunosuppressive environment.

Role of EBV: In EBV-positive RS cells, LMP1 mimics CD40 signaling and constitutively activates NF-κB. LMP2A mimics BCR signaling and supports RS cell survival. In EBV-negative cHL, NF-κB is activated by other mechanisms, such as loss of A20 (TNFAIP3) and IκBα mutations.

6. Symptoms

Painless lymphadenopathy: The most common presenting symptom, mainly starting in the neck (about 60-80%) and mediastinum (about 50-60%). The lymph nodes characteristically have a rubbery consistency and are painless. Alcohol-induced lymph node pain is a characteristic symptom of Hodgkin lymphoma, reported in about 5-10% of patients, but its mechanism is unclear.

B symptoms: Present in about 30-40% of patients at diagnosis, they have important implications for staging and prognosis.

Mediastinal mass symptoms: Bulky mediastinal disease can cause cough, dyspnea, chest pain, and superior vena cava syndrome (SVC syndrome; upper limb/facial edema, dyspnea). Dysphagia due to esophageal compression is also possible.

Pruritus: Generalized pruritus is a characteristic symptom occurring without jaundice. Cytokines such as IL-5, IL-13, and ECP (eosinophil cationic protein) are presumed to be involved in the mechanism. Pruritus is not included among B symptoms but is an important clinical clue suggesting Hodgkin lymphoma.

Splenomegaly and others: Splenomegaly occurs in about 20-30% of patients and suggests splenic involvement by Hodgkin lymphoma. Hepatomegaly (liver involvement) and bone marrow involvement (leukopenia, thrombocytopenia, anemia) may appear at advanced stages.

7. Signs

Mediastinal widening: Mediastinal widening is observed on chest X-ray, and bulky mediastinal disease is defined as a mediastinal diameter/thoracic diameter ratio of 1/3 or more on chest X-ray (MMR≥1/3). On CT it is confirmed as a mass of 10 cm or more (bulky disease).

Characteristics of lymphadenopathy: Painless, rubbery masses on palpation of cervical, supraclavicular, axillary, and inguinal lymph nodes. Bilateral cervical lymphadenopathy is common.

Laboratory findings:

Staging (Lugano Classification 2014): Stage Ⅰ (single lymph node region or single extralymphatic site), Stage Ⅱ (2 or more lymph node regions on the same side of the diaphragm), Stage Ⅲ (lymph node regions on both sides of the diaphragm), Stage Ⅳ (widespread extranodal involvement). A/B designation (absence/presence of B symptoms) and bulk (X symbol) are added.

IPS (International Prognostic Score): a score of 7 factors—serum albumin <4 g/dL, hemoglobin <10.5 g/dL, male sex, stage Ⅳ, age ≥45 years, white blood cells ≥15,000/μL, lymphocytes <600/μL or <8%. It stratifies prognosis, with 5-year freedom from treatment failure of 84% at 0 points and 42% at 7 points.

8. Screening

General population screening for Hodgkin lymphoma is not performed. However, surveillance in specific high-risk groups is clinically meaningful.

Surveillance for EBV infection: In HIV-positive individuals, surveillance for opportunistic infections (including EBV) is recommended when CD4 cell counts are low. In immunosuppressed transplant patients, monitoring of EBV viremia helps prevent lymphoproliferative disorders.

Post-treatment surveillance: After achieving complete remission, regular follow-up is essential for early detection of relapse. According to NCCN guidelines, clinical evaluation and blood tests are performed every 3-6 months for 2 years after completion of treatment, and CT every 1-2 years. PET-CT is performed when clinical relapse is suspected, and PET-CT for routine surveillance is not recommended (to minimize radiation exposure).

Surveillance for treatment toxicity: Regular surveillance for long-term toxicities related to anthracyclines (cardiotoxicity), bleomycin (pulmonary toxicity), and radiation therapy (secondary malignancies, cardiovascular disease, hypothyroidism) is important. In particular, in patients who received mediastinal radiation therapy, the risks of breast cancer (in women), lung cancer, and cardiovascular disease increase.

9. Diagnosis

Tissue biopsy (mandatory): The key to diagnosing Hodgkin lymphoma is identifying RS cells and the characteristic background in sufficient tissue. Excisional biopsy is most ideal. Core needle biopsy is also acceptable if sufficient tissue is obtained. Fine-needle aspiration (FNA) alone is insufficient for diagnosis.

Essential immunohistochemistry (IHC) panel:

Staging tests:

Clinical assessment tools: Treatment intensity is determined by calculating the IPS (International Prognostic Score) and assessing GHSG (German Hodgkin Study Group) risk factors (ESR≥50, or ESR≥30 with B symptoms; 3 or more lymph node regions; mediastinal mass ratio MMR≥1/3; extranodal lesions).

10. Treatment

Early stage (IA-IIA, favorable prognosis group)

Based on the GHSG HD10/HD13 studies, 2 cycles of ABVD + combined radiation therapy (involved-site radiation therapy of 30 Gy or more, ISRT) is the standard. If interim PET is negative (Deauville 1-2), treatment is limited to 2 cycles of ABVD, and if positive (3-5), treatment intensification is considered.

Early stage (IB-IIB or unfavorable prognosis group)

4 cycles of ABVD (or 2 cycles of escalated BEACOPP) + ISRT (30 Gy) is the standard. Deintensification or escalation strategies based on interim PET response are applied.

Advanced stage (ⅢA-ⅣB)

Two preferred regimens as of 2024:

Relapsed/refractory Hodgkin lymphoma (R/R cHL)

Nodular lymphocyte predominant (NLPHL)

Localized disease has a high remission rate with radiation therapy alone. Advanced NLPHL is treated with R-CHOP (rituximab + CHOP) or rituximab alone (low-burden disease). Because NLPHL has a higher risk of histologic transformation to DLBCL than cHL, biopsy is sometimes needed during follow-up.

11. Prognosis

Hodgkin lymphoma is one of the malignancies curable with appropriate treatment, and with modern treatment overall 5-year survival reaches about 85-90%.

Stage/subtype5-year survival5-year progression-free survival
Early stage, favorable prognosis group (IA, IIA)About 95-98%About 90-95%
Early stage, unfavorable prognosis group (IB, IIB, bulky)About 90-95%About 80-90%
Advanced stage (III-IV, NIVO-AVD)About 85-90%About 85-90% (SWOG S1826, 94% at 1 year)
Relapsed/refractory, after ASCTAbout 50-70%About 40-60%
Relapsed/refractory, ASCT not possible (anti-PD-1)Increasing reports of long-term survivalORR 65-87%

Prognostic factors: IPS score, stage, presence of B symptoms, mediastinal tumor size (bulky), interim PET response (Deauville score). Interim PET response is currently used as the strongest predictor of treatment response. When there is no relapse within 2 years after completion of treatment (complete metabolic remission, CMR), the likelihood of long-term survival is high.

Long-term toxicity: treatment-related cardiovascular disease, secondary malignancies (especially lung cancer, breast cancer, leukemia), hypothyroidism, reproductive dysfunction, and bleomycin pulmonary toxicity are the main long-term follow-up issues.

12. Prevention

There is currently no method that specifically prevents the development of Hodgkin lymphoma. However, management of the following risk factors may help.

HIV prevention and management: Prevention of HIV infection (safe sex, no needle sharing) and early initiation of antiretroviral therapy (ART) in people with HIV can lower the risk of HIV-associated Hodgkin lymphoma.

Minimizing EBV exposure: There is no specific preventive method, but EBV vaccine development is under study. In adolescents who have had infectious mononucleosis, monitoring for subsequent development of Hodgkin lymphoma may be meaningful.

Managing immunosuppression: In organ transplant patients, strategies to minimize immunosuppressants reduce the risk of lymphoma, including post-transplant lymphoproliferative disorder (PTLD).

Prevention of treatment toxicity (secondary prevention): In long-term follow-up after cure of Hodgkin lymphoma, screening for secondary malignancies (lung cancer and breast cancer after mediastinal radiation therapy)—chest CT, breast cancer screening (MRI)—is important. Not smoking and managing cardiovascular risk factors (hypertension, dyslipidemia, diabetes) also help lower the risk of treatment-related cardiovascular disease.


13. References

  1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17:68-114.
  2. Reed DM. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep. 1902;10:133-196.
  3. DeVita VT, et al. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73(6):881-895.
  4. Bonadonna G, et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36(1):252-259.
  5. Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378(4):331-344.
  6. Herrera AF, et al. Nivolumab plus AVD in advanced-stage classic Hodgkin's lymphoma. N Engl J Med. 2024;391(17):1599-1611.
  7. Kim SJ, et al. Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). Ann Hematol. 2011;91(1):93-101.
  8. Korean Society of Hematology. Clinical Practice Guideline for Hodgkin Lymphoma. 2023.
  9. NCCN Clinical Practice Guidelines: Hodgkin Lymphoma. Version 2.2025.
  10. Follows GA, et al. Guidelines for the first line management of classical Hodgkin lymphoma. Br J Haematol. 2014;166(1):34-49.